| Abstract |
Abstract: Objective: To explore the clinical efficacy of combination therapy with transcranial magnetic stimulation in first-episode adolescent depression patients. Method: Case data were collected and filed from March 2020 to March 2023. A total of 290 adolescent depression patients admitted to the hospital were included, and the participants were divided into 1:1 groups based on the "random number table" method, They were divided into the control group (treated with conventional medicine) and the observation group (treated with conventional medicine+cognitive therapy combined with transcranial magnetic stimulation, 145 cases were included respectively; the psychological score, sleep quality, cognitive function, and serum brain derived neurotrophin level of the two groups were observed and compared. Results: After treatment, the scores of Hamilton Depression Rating Scale (HAMD) in both groups showed a downward trend, and the observation group was lower than the control group (P<0.05); After treatment, the ASHQ scores of both groups of adolescents decreased to varying degrees, and the observed group showed a greater decrease than the control group (P<0.05); After treatment, the scores of the Montreal Cognitive Function Assessment Scale (MoCA) in both groups increased, and the scores of the observation group were higher than those of the control group (P<0.05); After treatment, the level of serum brain-derived neurotrophin (BNEF) in both groups showed an upward trend, and the observed increase value was significantly higher than that in the control group (P<0.05). Conclusion: Cognitive therapy combined with transcranial magnetic stimulation can play a role in regulating the body neurotrophin in the treatment of first-episode adolescent depression, which can significantly improve the depressive degree of patients, further improve their sleep quality, and have a significant effect on the improvement of cognitive function of patients.
|